TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

NCT02586675 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

7

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Breast Cancer - Female
Breast Cancer - Male

Interventions

DRUG: Tamoxifen
DRUG: Ribociclib
DRUG: Goserelin

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]